Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NovoCure's Enterprise Value is MXN31,000 Mil.
NovoCure's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-2,165 Mil. Therefore, NovoCure's EV-to-EBIT ratio for today is -14.32.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, NovoCure's Enterprise Value is MXN31,000 Mil.
NovoCure's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-1,873 Mil. Therefore, NovoCure's EV-to-EBITDA ratio for today is -16.55.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, NovoCure's Enterprise Value is MXN31,000 Mil.
NovoCure's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was MXN12,549 Mil. Therefore, NovoCure's EV-to-Revenue ratio for today is 2.47.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, NovoCure's Enterprise Value is MXN31,000 Mil.
NovoCure's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-454 Mil. Therefore, NovoCure's EV-to-FCF ratio for today is -68.27.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
NovoCure's current Enterprise Value is MXN31,000 Mil.
NovoCure's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-2,165 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
NovoCure's current Enterprise Value is MXN31,000 Mil.
NovoCure's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-1,873 Mil.
NovoCure's current Enterprise Value is MXN31,000 Mil.
NovoCure's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN12,549 Mil.
NovoCure's current Enterprise Value is MXN31,000 Mil.
NovoCure's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-49 Mil.
NovoCure's current Enterprise Value is MXN31,000 Mil.
NovoCure's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-454 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure Enterprise Value Related Terms
NovoCure Enterprise Value Historical Data
* Premium members only.
The historical data trend for NovoCure's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NVCRN vs NEOG, AXGN, UFPT: Enterprise Value Comparison
For the Medical Devices subindustry, NovoCure's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Enterprise Value distribution charts can be found below:
* The bar in red indicates where NovoCure's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
NovoCure's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of MXN31,000 Mil mean?
NovoCure (MEX:NVCRN) has a Enterprise Value of MXN31,000 Mil as of Aug. 14, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on NovoCure and its competitors.
Is NovoCure's Enterprise Value too high?
NovoCure's current Enterprise Value is MXN31,000 Mil. Overall, NovoCure has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Enterprise Value compare to NEOG and AXGN?
NovoCure's Enterprise Value of MXN31,000 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on NovoCure and its competitors. NovoCure's current Enterprise Value is MXN31,000 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
NovoCure (MEX:NVCRN) has a current Enterprise Value of MXN31,000 Mil. The stock's GF Value™ is MXN338.44, compared to a current price of MXN322.39 — trading 4.7% below its estimated fair value. The current Enterprise Value is MXN31,000 Mil. NovoCure's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For NovoCure (MEX:NVCRN), the current Enterprise Value is MXN31,000 Mil as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovoCure (MEX:NVCRN) Overvalued in 2026?
Based on GuruFocus' analysis, NovoCure stock appears to be undervalued.
The current stock price of MXN322.39 is trading 4.7% below its estimated GF Value™ of MXN338.44.
Key valuation signals for MEX:NVCRN:
Enterprise Value: MXN31,000 Mil
GF Value™: MXN338.44 vs. price of MXN322.39 (4.7% below fair value)
No single metric tells the full story. See the MEX:NVCRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
70GF Score
Get the complete analysis for MEX:NVCRN
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NVCRN has been successfully added to your 
